BioStock: Cyxone CRO agreement signals Phase IIb RA trial moving forward as planned
In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations Agreement with an internationally renowned clinical contract research organisation. BioStock contacted CEO Tara Heitner to learn more.
Read the interview with Cyxone's CEO Tara Heitner at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/